A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation

Model scores of the 29,894 trials active now.

Model score 24% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 20% of the time (389 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2021-10-18. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: enrollmentchronicheartother protocolprotocol defined
  Phrases that lowered it: pharmacokineticsgastricparticipantsdisorderbleeding
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 10.5% (raises risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 100 (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 15.7% (lowers risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Minimum age: 0.08 (lowers risk) · Who can join
• Sponsor's past trials: 551 (raises risk) · Sponsor's track record
• Collaborators: 2 (lowers risk) · Design
• Maximum age: 17 (raises risk) · Who can join
• Disease area, cancer: No (lowers risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 80.9% (lowers risk) · Drug's FDA history
• Drugs with FDA adverse-event history: 4 (lowers risk) · Drug's FDA history
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Drug's FAERS reports before start: 178643 (lowers risk) · Drug's FDA history
• Blinding: none (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study to Evaluate a Single Dose of Apixaban in Pediatric Participants at Risk for a Thrombotic Disorder NCT01707394 · started 2013 · scored riskier than 16% of active trials completed
• Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease NCT03395639 · started 2018 · scored riskier than 34% of active trials completed
• Oral Anticoagulant Apixaban for Treatment of Venous Thromboembolism NCT04041843 · started 2017 · scored riskier than 96% of active trials completed
• A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase NCT02369653 · started 2015 · scored riskier than 61% of active trials completed
• EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis NCT02234843 · started 2014 · scored riskier than 30% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.